



December 5, 2019

Via email: AGO.highcostprescriptiondrugs@vermont.gov

Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609

RE: Notice of a New Prescription Drug Pursuant to 18 V.S.A. § 4637(b)

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Global Blood Therapeutics, Inc., is providing notice of the introduction on December 4, 2019 of a new prescription drug to market with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program. The new drug being launched is:

Oxbryta™ (Voxelotor): NDC: 72786-0101-01

Please contact me if you have any questions.

Sincerely,

A handwritten signature in blue ink, appearing to read "Tricia Suvari", is written over the typed name and title.

Tricia Suvari
Chief Legal Officer